The mission of the OSUCCC Proteomics Shared Resource (PSR) is to advance the quality of cancer research while increasing productivity of OSUCCC members at reduced costs through providing high quality instrumentation and expert resources. The PSR provides instrumentation, scientific expertise and shared research services needed for the identification of proteins, protein modifications and protein biomarkers. The methods in proteomic analysis supported by the PSR include protein extraction from biopsies or ce cu tures, 2- dimensional protein separation, protein identification by MALDI-TOF and electrospray ionization coupled with liquid chromatography (LC) mass spectrometry and database searching, protein quantification through image analysis of 2D-gels and protein pattern recognition by SELDI-TOF mass spectrometry for serum analyses. The PSR is designed to provide affordable and high quality service in each of these areas, based on a cost-effective charge-back system. Under the leadership of Dr. Ming-Daw Tsai, the PSR facility provides technical expertise for OSUCCC researchers to submit samples for proteomic analysis as well as a collaborative environment for researchers to discuss with the PSR staff on how to solve a research problem using cutting-edge technology so that these researchers can more effectively and efficiently solve problems of chemical and protein biomarker and diagnosis on cancer samp es and research projects. Since 1999, over $3.8 M of institutional support has been invested in the development of the PSR, with almost half of that amount supporting the purchase of state-of-the-part instrumentation. Although relatively new, the PSR has shown an increasing usage by OSUCCC members, now exceeding 30 members representing all 6 of the OSUCCC research programs. At present, OSUCCC member usage of the PSR represents approximately one-third of the total usage of the facility. Based on historical growth as well as planned growth from new recruitment efforts within the OSUCCC and the role proteomics is beginning to play in profiling the cancer cell, it is projected that OSUCCC members will represent more than 50% of the total PSR usage in the new project period. We now request CCSG funding for the PSR that will provide `23% of the total support for this important full Shared Resource over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630238
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$173,973
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Chen, Shuliang; Bonifati, Serena; Qin, Zhihua et al. (2018) SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-?B and interferon pathways. Proc Natl Acad Sci U S A 115:E3798-E3807

Showing the most recent 10 out of 2602 publications